Found 25 matching trials
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer PHASE2 TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 ...
Show More Status
Active Not Recruiting
Location
University of Hawaii
Learn More & Join Trial
Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma PHASE2 This phase II trial tests how well niraparib and dostarlimab work in treati...
Show More Status
Active Not Recruiting
Location
Ohio State University Comprehensive Cancer Center
Learn More & Join Trial
Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment PHASE3 Randomized phase 3 trial evaluating niraparib plus dostarlimab vs chemother...
Show More Location
Azienda Ospedaliera Spedali Civili
Learn More & Join Trial
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors PHASE2 The purpose of this study is to find out whether the study drug, TSR-042, f...
Show More Location
Hartford Healthcare (Data Collection)
Learn More & Join Trial
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors PHASE1 This is a multi-center, open-label, first-in-human Phase 1 study evaluating...
Show More Status
Active Not Recruiting
Location
GSK Investigational Site
Learn More & Join Trial
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery PHASE2 This study will test whether the combination of radiation and Dostarlimab i...
Show More Location
Memorial Sloan Kettering Basking Ridge (All Protocol Activites)
Learn More & Join Trial
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib PHASE2 Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressi...
Show More Learn More & Join Trial
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer PHASE3 Ovarian cancer is a heterogeneous disease, characterized by complex molecul...
Show More Status
Active Not Recruiting
Location
GSK Investigational Site
Learn More & Join Trial
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants PHASE2 This is a multicenter, open-label, phase 2 study to evaluate the efficacy a...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas PHASE2 This phase II trial studies the effect of niraparib and dostarlimab in trea...
Show More Status
Active Not Recruiting
Location
M D Anderson Cancer Center
Learn More & Join Trial